$154.80
-2.26[-1.44%]
At close: May 28
$154.80
0[0.00%]
After Hours: 6:23PM EDT
Latest News for AbbVie Stock (NYSE:ABBV)
AbbVie Stock (NYSE: ABBV)
Categories: All
Tuesday, May 28, 2024
Friday, May 24, 2024
Thursday, May 23, 2024
Wednesday, May 22, 2024
Saturday, May 18, 2024
Friday, May 17, 2024
- AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': AnalystVandana Singh - May 17, 2024, 1:47PM
- The Analyst Verdict: AbbVie In The Eyes Of 5 ExpertsBenzinga Insights - May 17, 2024, 9:00AM
- AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative ColitisBenzinga Newsdesk - May 17, 2024, 7:34AM
- Cantor Fitzgerald Initiates Coverage On AbbVie with Overweight Rating, Announces Price Target of $200Benzinga Newsdesk - May 17, 2024, 7:16AM
Thursday, May 16, 2024
Tuesday, May 14, 2024
Monday, May 13, 2024
Friday, May 10, 2024
Wednesday, May 08, 2024
Friday, May 03, 2024
Thursday, May 02, 2024
Tuesday, April 30, 2024
Monday, April 29, 2024
- Barclays Maintains Overweight on AbbVie, Lowers Price Target to $187Benzinga Newsdesk - Apr 29, 2024, 11:26AM
- Peeling Back The Layers: Exploring AbbVie Through Analyst InsightsBenzinga Insights - Apr 29, 2024, 11:01AM
- BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180Benzinga Newsdesk - Apr 29, 2024, 10:09AM
- Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This WeekShanthi Rexaline - Apr 29, 2024, 1:51AM
Friday, April 26, 2024
- Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket CostVandana Singh - Apr 26, 2024, 2:41PM
- Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?Piero Cingari - Apr 26, 2024, 1:45PM
- AbbVie shares are trading lower, reversing from earlier strength on Q1 earnings.Benzinga Newsdesk - Apr 26, 2024, 1:24PM
- Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookVandana Singh - Apr 26, 2024, 9:54AM
- AbbVie shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY24 adjusted EPS guidance above estimates.Benzinga Newsdesk - Apr 26, 2024, 7:43AM
- AbbVie Is Raising Its 2024 Adjusted EPS Guidance From $10.97-$11.17 To $11.13-$11.33, Which Includes An Unfavorable Impact Of $0.08 Per Share Related To Acquired IPR&D And Milestones Expense, Versus Consensus Of $11.12Benzinga Newsdesk - Apr 26, 2024, 7:38AM
- AbbVie Q1 2024 Adj EPS $2.31 Beats $2.23 Estimate, Sales $12.310B Beat $11.923B EstimateBenzinga Newsdesk - Apr 26, 2024, 7:36AM
- Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over YetShanthi Rexaline - Apr 26, 2024, 6:48AM
Thursday, April 25, 2024
- AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head StudyVandana Singh - Apr 25, 2024, 1:58PM
- AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Worst Pruritus Numerical Rating Scale Of 0 Or 1 At Week 16Benzinga Newsdesk - Apr 25, 2024, 8:09AM
Tuesday, April 23, 2024
Sunday, April 21, 2024
Thursday, April 18, 2024
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyVandana Singh - Apr 18, 2024, 1:44PM
- AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also MetBenzinga Newsdesk - Apr 18, 2024, 8:32AM
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst UpgradesVandana Singh - Apr 16, 2024, 2:25PM
- FDA Says Counterfeit Version Of Botox Found In Multiple States; Alerting Health Care Professionals & Consumers That Unsafe Counterfeit Versions Of Botox Found In Multiple States & Administered To Consumers; Currently, There Is No Indication That The Reported Events Were Linked To Abbvie's FDA-Approved Botox; Aware Of Adverse Events, Including Hospitalizations, Linked To Counterfeit BotoxBenzinga Newsdesk - Apr 16, 2024, 9:54AM
Monday, April 15, 2024
Friday, April 12, 2024
- What's Going On AbbVie Stock On Friday?Vandana Singh - Apr 12, 2024, 2:19PM
- Smart Money Is Betting Big In ABBV OptionsBenzinga Insights - Apr 12, 2024, 10:04AM
- AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA) for Preventive Treatment of MigraineBenzinga Newsdesk - Apr 12, 2024, 7:31AM